This scenario might be possible if, for instance, TNF-TNFR1 signaling inhibition is beneficial for PD in older age due to anti-inflammatory effects, but detrimental earlier in life for other reasons (e.g., increased susceptibility to infections or reduced neurodevelopment). This evidence concerns the gene TNFRSF1A and Parkinson disease.